Milestone Pharmaceuticals Inc. Board of Directors

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Mr. Joseph G. Oliveto M.B.A.

Mr. Joseph G. Oliveto M.B.A.

CEO, President & Director

Mr. Lorenz Muller

Mr. Lorenz Muller

Chief Commercial Officer

Dr. Philippe Douville M.B.A., Ph.D.

Dr. Philippe Douville M.B.A., Ph.D.

Founder, Strategic Advisor & Member of Scientific Advisory Board

Ms. Anita Holz

Ms. Anita Holz

VP & Head of Medical Affairs

Dr. Philip T. Sager FACC, FAHA, FHRS, M.D.

Dr. Philip T. Sager FACC, FAHA, FHRS, M.D.

Chief Medical Advisor & Member of the Scientific Advisory Board

Dr. Guy Rousseau

Dr. Guy Rousseau

SVP of Regulatory Affairs and Quality Management

Ms. Kim Fox

Ms. Kim Fox

Vice President of Communications

Mr. Amit Hasija

Mr. Amit Hasija

CFO & Executive VP of Corporate Development

Mr. Jeffrey Nelson

Mr. Jeffrey Nelson

Chief Operating Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.